Patents by Inventor Raul Andino-Pavlovsky
Raul Andino-Pavlovsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230233669Abstract: The present disclosure generally relates to, inter alia, to nucleic acid constructs encoding a modified enterovirus genome that is devoid of partial or complete nucleic acid sequences encoding viral structural proteins. The disclosure also provides compositions and methods useful for producing defective interfering particles (DIPs) of enteroviruses, and for the prevention and/or treatment of various health conditions such as immune diseases and viral infections.Type: ApplicationFiled: July 2, 2021Publication date: July 27, 2023Inventors: Raul ANDINO-PAVLOVSKY, Yinghong XIAO, Gilad DOITSH, Robert NAKAMURA, Dale TALBOT
-
Publication number: 20230201245Abstract: The present disclosure provides materials and methods for treating or preventing an infection from a virus such as an RNA virus, inhibiting replication of a vims in a cell, inhibiting translation of viral proteins in a cell infected with a virus, inhibiting prolyl hydroxylation in a cell infected with a vims, preventing or inhibiting viral-induced remodeling of a polysome in a cell, and identifying a polysome-associated protein in a cell infected by a virus.Type: ApplicationFiled: June 4, 2021Publication date: June 29, 2023Inventors: Judith Frydman, Raul Andino-Pavlovsky, Ranen Aviner
-
Patent number: 8163548Abstract: The present invention provides recombinant bicistronic flaviviruses, particularly live attenuated recombinant bicistronic flavivirus, which comprise, in order from 5? to 3?, a viral 5?UTR, an ORF encoding all viral proteins, an internal ribosome entry site, an exogenous nucleotide sequence that encodes an exogenous polypeptide, and a viral 3?UTR. Infection of a host cell with a recombinant flavivirus provides for expression of the exogenous nucleic acid in a host cell. Such recombinant flavivirus are useful for delivering a protein to a mammalian host; and for eliciting an immune response to the exogenous polypeptide.Type: GrantFiled: November 23, 2010Date of Patent: April 24, 2012Assignee: The Regents of the University of CaliforniaInventors: Raul Andino-Pavlovsky, Andres McAllister-Moreno
-
Publication number: 20110135682Abstract: The present invention provides recombinant bicistronic flaviviruses, particularly live attenuated recombinant bicistronic flavivirus, which comprise, in order from 5? to 3?, a viral 5?UTR, an ORF encoding all viral proteins, an internal ribosome entry site, an exogenous nucleotide sequence that encodes an exogenous polypeptide, and a viral 3?UTR. Infection of a host cell with a recombinant flavivirus provides for expression of the exogenous nucleic acid in a host cell. Such recombinant flavivirus are useful for delivering a protein to a mammalian host; and for eliciting an immune response to the exogenous polypeptide.Type: ApplicationFiled: November 23, 2010Publication date: June 9, 2011Applicant: The Regents of the University of CaliforniaInventors: RAUL ANDINO-PAVLOVSKY, ANDRES MCALLISTER-MORENO
-
Patent number: 7871814Abstract: The present invention provides recombinant bicistronic flaviviruses, particularly live attenuated recombinant bicistronic flavivirus, which comprise, in order from 5? to 3?, a viral 5?UTR, an ORF encoding all viral proteins, an internal ribosome entry site, an exogenous nucleotide sequence that encodes an exogenous polypeptide, and a viral 3?UTR. Infection of a host cell with a recombinant flavivirus provides for expression of the exogenous nucleic acid in a host cell. Such recombinant flavivirus are useful for delivering a protein to a mammalian host; and for eliciting an immune response to the exogenous polypeptide.Type: GrantFiled: May 9, 2002Date of Patent: January 18, 2011Assignee: The Regents of the University of CaliforniaInventors: Raul Andino-Pavlovsky, Andres McAllister-Moreno
-
Publication number: 20100093824Abstract: The present invention provides methods of treating an RNA viral infection, generally involving administering an agent that reduces the activity of a host cell protein required for maturation of a viral protein, where the emergence of variant virus resistant to the agent is reduced. The present invention further provides combination therapies for viral infection, involving administration of two or more agents that reduce the activity of a host cell protein required for maturation of a viral protein.Type: ApplicationFiled: November 28, 2007Publication date: April 15, 2010Inventors: Judith Frydman, Raul Andino-Pavlovsky, Ron Geller
-
Patent number: 7390646Abstract: The present invention provides a live, attenuated, invasive bacterium that infects a mammalian host cell, and releases exogenous RNA into the cytoplasm of the host cell. The present invention further provides compositions, including immunogenic compositions, comprising a subject bacterium. The present invention provides methods of delivering an RNA to a eukaryotic host cell in vitro, ex vivo, or in vivo. The present invention provides methods of delivering a protein to a host cell in vitro, ex vivo, or in vivo. The present invention provides methods of controlling expression of a target gene in a eukaryotic host cell. The present invention provides methods of inducing an immune response in a mammalian host to a polypeptide antigen, the method involving administering to the host a subject bacterium, wherein the antigen is encoded by the exogenous RNA produced by the bacterium.Type: GrantFiled: September 17, 2004Date of Patent: June 24, 2008Assignee: The Regents of the University of CaliforniaInventors: Raul Andino-Pavlovsky, Marco Vignuzzi, Derek H. Wells
-
Publication number: 20050118193Abstract: The present invention provides a live, attenuated, invasive bacterium that infects a mammalian host cell, and releases exogenous RNA into the cytoplasm of the host cell. The present invention further provides compositions, including immunogenic compositions, comprising a subject bacterium. The present invention provides methods of delivering an RNA to a eukaryotic host cell in vitro, ex vivo, or in vivo. The present invention provides methods of delivering a protein to a host cell in vitro, ex vivo, or in vivo. The present invention provides methods of controlling expression of a target gene in a eukaryotic host cell. The present invention provides methods of inducing an immune response in a mammalian host to a polypeptide antigen, the method involving administering to the host a subject bacterium, wherein the antigen is encoded by the exogenous RNA produced by the bacterium.Type: ApplicationFiled: September 17, 2004Publication date: June 2, 2005Inventors: Raul Andino-Pavlovsky, Marco Vignuzzi, Derek Wells
-
Patent number: 6893643Abstract: The present invention provides recombinant yellow fever viruses (YFV), particularly live attenuated recombinant YFV, which comprise exogenous (i.e., non-YFV) nucleotide sequences which encode exogenous (i.e., non-YFV) amino acid sequences. These recombinant YFV viruses comprise an exogenous nucleic acid. Infection of a host cell with a recombinant YFV provides for expression of the exogenous nucleic acid in a host cell and production of an antigenic polypeptide encoded by the exogenous nucleic acid. Such recombinant YFV are useful in eliciting an immune response to the exogenous polypeptide.Type: GrantFiled: March 6, 2003Date of Patent: May 17, 2005Assignee: The Regents of the University of CaliforniaInventors: Raul Andino-Pavlovsky, Andres McAllister-Moreno
-
Publication number: 20040241821Abstract: The present invention provides recombinant bicistronic flaviviruses, particularly live attenuated recombinant bicistronic flavivirus, which comprise, in order from 5′ to 3′, a viral 5′UTR, an ORF encoding all viral proteins, an internal ribosome entry site, an exogenous nucleotide sequence that encodes an exogenous polypeptide, and a viral 3′UTR. Infection of a host cell with a recombinant flavivirus provides for expression of the exogenous nucleic acid in a host cell. Such recombinant flavivirus are useful for delivering a protein to a mammalian host; and for eliciting an immune response to the exogenous polypeptide.Type: ApplicationFiled: July 14, 2004Publication date: December 2, 2004Inventors: Raul Andino-Pavlovsky, Andres McCallister-Moreno
-
Publication number: 20030157128Abstract: The present invention provides recombinant yellow fever viruses (YFV), particularly live attenuated recombinant YFV, which comprise exogenous ( i.e., non-YFV) nucleotide sequences which encode exogenous (i.e., non-YFV) amino acid sequences. These recombinant YFV viruses comprise an exogenous nucleic acid. Infection of a host cell with a recombinant YFV provides for expression of the exogenous nucleic acid in a host cell and production of an antigenic polypeptide encoded by the exogenous nucleic acid. Such recombinant YFV are useful in eliciting an immune response to the exogenous polypeptide.Type: ApplicationFiled: March 6, 2003Publication date: August 21, 2003Inventors: Raul Andino-Pavlovsky, Andres McAllister-Moreno
-
Patent number: 6589531Abstract: The present invention provides recombinant yellow fever viruses (YFV), particularly live attenuated recombinant YFV, which comprise exogenous (i.e., non-YFV) nucleotide sequences which encode exogenous (i.e., non-YFV) amino acid sequences. These recombinant YFV viruses comprise an exogenous nucleic acid. Infection of a host cell with a recombinant YFV provides for expression of the exogenous nucleic acid in a host cell and production of an antigenic polypeptide encoded by the exogenous nucleic acid. Such recombinant YFV are useful in eliciting an immune response to the exogenous polypeptide.Type: GrantFiled: September 1, 2000Date of Patent: July 8, 2003Assignee: The Regents of the University of CaliforniaInventors: Raul Andino-Pavlovsky, Andres McAllister-Moreno
-
Publication number: 20030068332Abstract: The present invention provides a population of live attenuated recombinant replication-competent viruses, which population comprises at least two member viruses, each of the member viruses comprising a nucleotide sequence encoding a different antigenic polypeptide from a source other than a parent virus from which the recombinant virus was derived. When a eukaryotic cell of a mammalian host is infected with a member of the population, the nucleotide sequence is expressed, the antigenic polypeptide is produced, and elicits an immune response. The invention further provides compositions, including immunogenic compositions, comprising a subject virus population. The invention further provides methods of eliciting an immune response to a polypeptide in an individual, involving administering a subject virus population. The invention further provides devices for use in eliciting an immune response.Type: ApplicationFiled: March 22, 2002Publication date: April 10, 2003Inventors: Raul Andino-Pavlovsky, Shane Crotty